Adimab
Lebanon · Founded 2007
About Adimab
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Company Facts
- Founded: 2007
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $45.5M
- Last round: Series Unknown (Jan 2020)
- Website: adimab.com
- Phone: (603) 643-7110
Industries & Categories
Biotechnology, Collaboration, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/adimab-158291 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.